Gilead investing £19.6 million into UK expansion
Gilead Sciences is to create new UK commercial headquarters in London and expand its existing operations in the country.
Read MoreAuthor: Kevin Grogan
Pfenex and Hospira eye Lucentis biosimilar promise
Pfenex and Hospira, which is in the process of being acquired by Pfizer, are teaming up to develop the former’s biosimilar of Roche and Novartis’ eye blockbuster Lucentis.
Read MoreRoche buys German genomics group Signature
Roche has hit the acquisition trail again to buy privately-held Signature Diagnostics of Germany.
Read MoreAmgen’s Kearney to replace Pfizer’s Emms as ABPI president
The Association of the British Pharmaceutical Industry has appointed Amgen’s John Kearney to take over as its new president from Pfizer’s Jonathan Emms who is moving to New York after a promotion at the US giant.
Read MoreNobel winner’s stem cell firm sets crowdfunding record
Cell Therapy of Wales has raised nearly £700,000, setting a world record for biotech crowdfunding to finance its breakthrough stem cell medicine, Heartcel.
Read More- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
